HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Brady, C. S. Articles by Stern, P. L. Search for Related Content PubMed PubMed Citation Articles by Brady, C. S. Articles by Stern, P. L. Agricola Articles by Brady, C. S. Articles by Stern, P. L.

Human papillomavirus type 16 E6 variants in cervical carcinoma: relationship to host genetic factors and clinical parameters

Departments of Immunology¹ and Cancer Genetics², Paterson Institute for Cancer Research, Christie Hospital NHS Trust, Wilmslow Road, Manchester M20 4BX, UK
Transplantation Laboratory, Manchester Royal Infirmary, Oxford Road, Manchester M13 9WL, UK³

Author for correspondence: Peter Stern. Fax +44 161 446 3109. e-mail pstern{at}picr.man.ac.uk

Infection with human papillomavirus type 16 (HPV-16) confers a high risk for the development of cervical neoplasia. Variants of this virus may interact differentially with host genetic factors, possibly altering the disease course. Thus, HPV-16 E6 variants may differ in their ability to degrade p53 whereas the polymorphic p53 alleles may provide more or less susceptible substrates for the viral oncogene product. Also, E6 variants may differ in immunogenicity by generating different peptides for presentation by polymorphic HLA molecules to specific T cells. This study examines HPV-16 E6 sequence variation in cervical carcinomas from the UK and its relationship to polymorphism of HLA and p53 and to clinical parameters. Sequence analysis of the HPV-16 E6 ORF from 77 tumour biopsies detected the viral prototype sequence in 38% of cases. The most common variation detected was a T to G transition at base pair 350, resulting in an amino acid change from a leucine to a valine. Overall, the frequencies of 350T and 350G sequences were similar (49·4% and 50·6% respectively). Other mutations of lower frequencies were detected together with and independently of 350G. HPV-16 E6 sequence variation at base pair 350 did not correlate with HLA genotype or clinical outcome. There was no difference in the distribution of p53 proline and arginine alleles between HPV-16-positive cervical carcinoma patients and local controls, and no influence on clinical outcome; however, there was a trend for an increased frequency of p53 arginine homozygotes among the 350T carcinoma patients.

This article has been cited by other articles:

				Z. Chen, M. Terai, L. Fu, R. Herrero, R. DeSalle, and R. D. Burk Diversifying Selection in Human Papillomavirus Type 16 Lineages Based on Complete Genome Analyses J. Virol., June 1, 2005; 79(11): 7014 - 7023. [Abstract] [Full Text] [PDF]

				A. Koushik, R. W. Platt, and E. L. Franco p53 Codon 72 Polymorphism and Cervical Neoplasia: A Meta-Analysis Review Cancer Epidemiol. Biomarkers Prev., January 1, 2004; 13(1): 11 - 22. [Abstract] [Full Text] [PDF]

				L. F. Xi, J. J. Carter, D. A. Galloway, J. Kuypers, J. P. Hughes, S. K. Lee, D. E. Adam, N. B. Kiviat, and L. A. Koutsky Acquisition and Natural History of Human Papillomavirus Type 16 Variant Infection among a Cohort of Female University Students Cancer Epidemiol. Biomarkers Prev., April 1, 2002; 11(4): 343 - 351. [Abstract] [Full Text] [PDF]